āshibio Presents Biomarker Data Supporting Vantictumab Development for ADO2 and a Prevalence Estimate of CLCN7-Related ADO2 of 1–4 per 20,000 Individuals

Posted on by sHq_LoGiNz

BURLINGAME, Calif.–(BUSINESS WIRE)–āshibio presented new clinical biomarker and genetic prevalence data supporting the development of vantictumab for ADO2 at ASBMR 2026.

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.